Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Opipramol dihydrochloride

CAS No.

909-39-7

Innovator/marketer

Insidon

Polymorphic form

Amorphous

Therapeutic Area

Nervous system

Status

Commercial

EU DMF readiness

Drug description:

Opipramol hydrochloride acts as an anxiolytic and antidepressant agent.
Opipram is indicated for the treatment of generalized anxiety disorder (GAD) and somatoform disturbances.
It is formulated as film-coated tablets for oral route of administration.

Mechanism of action:

Opipramol is a tricyclic antidepressive agent. Opipramol acts as a high affinity sigma receptor agonist, primarily of the σ1 subtype, but also of the σ2 subtype with lower affinity. Cyclic antidepressants block the absorption of the neurotransmitters serotonin and norepinephrine, making more of these chemicals available in the brain.

DISCLAIMER
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).

OK